How can anyone let alone Lockitt say what the MC should be of a...

How can anyone let alone Lockitt say what the MC should be of a spec bio company whose trial results could be a complete success, in which case, Itsa, the SP should then reflect your DD on sales value per unit, or a fail, in which case, in the absence of the drug having other applications, we can expext the MC to go to zero

Your ongoing constant rhetoric about the SP being forwars looking does not apply here.. this is a binary outcome scenario in which the trial is successful (and the SP gets rerated) or not (SP goes to pot) and nothing you say ten times a day between now and then will change that or the MC...